Stonehage Fleming Financial Services Holdings Ltd bought a new stake in Illumina, Inc. (NASDAQ:ILMN – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,223 shares of the life sciences company’s stock, valued at approximately $918,000.
Several other institutional investors also recently made changes to their positions in ILMN. Capital World Investors increased its holdings in shares of Illumina by 0.6% in the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after purchasing an additional 124,323 shares in the last quarter. BlackRock Inc. purchased a new stake in Illumina during the second quarter worth about $3,374,423,000. State Street Corp boosted its holdings in Illumina by 3.2% during the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after buying an additional 190,324 shares in the last quarter. WCM Investment Management LLC grew its position in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares during the period. Finally, AQR Capital Management LLC grew its position in Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after buying an additional 1,028,099 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.
Illumina Stock Up 1.3%
Shares of NASDAQ ILMN opened at $227.69 on Friday. The firm’s 50-day moving average is $192.98 and its two-hundred day moving average is $155.18. The company has a market capitalization of $34.38 billion, a PE ratio of 42.48, a price-to-earnings-growth ratio of 3.16 and a beta of 1.45. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $231.81. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.
Insider Buying and Selling at Illumina
In other Illumina news, SVP Christensen Jakob Wedel sold 1,033 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total transaction of $123,000.00. Following the completion of the transaction, the insider directly owned 20,338 shares of the company’s stock, valued at approximately $4,067,600. This represents a 2.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 2,034,688 shares of company stock worth $417,970,281. 2.90% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
ILMN has been the subject of a number of research reports. Citigroup lifted their price target on shares of Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research report on Monday, August 3rd. Deutsche Bank Aktiengesellschaft downgraded Illumina to a “hold” rating in a research note on Wednesday, August 5th. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. TD Cowen boosted their target price on Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Finally, Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Illumina has an average rating of “Hold” and a consensus target price of $188.40.
Read Our Latest Report on ILMN
Illumina Profile
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Stories
- Five stocks we like better than Illumina
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
